Inclusion Criteria:  Has PROS or PS and is currently being actively treated with miransertib as part of Study MK-7075-002 (NCT03094832) or ArQule's Compassionate Use and Extended Access Program (CU/EAP, NCT03317366)  Exclusion Criteria:  Has previously discontinued miransertib due to related SAEs or other intolerance of miransertib Received other investigational agents, if any, that were administered between leaving Study MK-7075-02 or ArQule's CU/EAP and entering this trial Receives inhibitors of the mechanistic target of rapamycin (mTOR) pathway (eg, sirolimus, everolimus) Receives immunosuppressive therapies Receives continuous high dose steroids